Next Article in Journal
18F-Fluorocholine PET and Multiphase CT Integrated in Dual Modality PET/4D-CT for Preoperative Evaluation of Primary Hyperparathyroidism
Previous Article in Journal
Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview
Open AccessReview

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

1
Department of Pharmaceutical Science, University of Connecticut, Storrs, CT 06269, USA
2
Department of Genetics, Yale University, New Haven, CT 06520, USA
3
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5671, USA
4
Department of Chemistry, Wesleyan University, Middletown, CT 06459, USA
5
Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Iowa, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 2004; https://doi.org/10.3390/jcm9062004
Received: 24 April 2020 / Revised: 20 June 2020 / Accepted: 24 June 2020 / Published: 26 June 2020
(This article belongs to the Section Pharmacology)
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies. View Full-Text
Keywords: RNA; antisense oligonucleotides; chemical modifications; clinical trials RNA; antisense oligonucleotides; chemical modifications; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Dhuri, K.; Bechtold, C.; Quijano, E.; Pham, H.; Gupta, A.; Vikram, A.; Bahal, R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med. 2020, 9, 2004.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop